NCEL
NASDAQ
$3.97
NLS Pharmaceutics Ltd (NCEL)
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Switzerland.
Sector:
Healthcare
Industry:
Biotechnology
Target: $23 (+479.35%)
Market Cap
$19M
Free Cash Flow Yield
-14.71%
Beta (5Y)
0.59
Price Chart
Valuation
Market Cap$19M
P/B2.96
Profitability
EBITDA-$2.51M
EPS-$1.73
Financial Health
Debt-to-Equity4.9%
Free Cash Flow Yield-14.71%
Growth & Risk
Beta (5Y)0.59
Sharpe Ratio-0.92